Compare Illumina, Inc. (ILMN) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs MasterCard Inc — how do they compare? Illumina, Inc. trades at $278.99 (market cap $39.95B), while MasterCard Inc trades at $587.31 (market cap $503.50B). The key difference: MasterCard Inc is far larger — about 12.6× Illumina, Inc.'s market cap, and MasterCard Inc pays a 0.61% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and MasterCard Inc for 134 Days on average.
| ILMN | MA | |
|---|---|---|
Market Cap | $39.95B | $503.50B |
Volume | 3,169,503 | 3,390,859 |
Sector | Health | Financials |
52-Week High | $293.69 | $599.86 |
52-Week Low | $91.00 | $471.55 |
Typical Hold Time | 83 Days | 134 Days |
Enterprise Value | $41.31B | $516.53B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $278.17, up 3.89% today and near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent inclusion in the S&P 500 and positive analyst upgrades reflect growing institutional confidence. Revenue remains stable at $4.34B for 2025 with improved profitability, delivering $850M net income after previous losses.
The outlook remains positive with sequencing growth and AI initiatives driving momentum, though elevated valuation ratios and China market headwinds present risks. Analyst consensus leans bullish with 54% buy ratings, but the current price exceeds the $241 consensus target, suggesting near-term consolidation potential before further upside.
Mastercard (MA) trades at $589.14, up 3.35% today, showing strong momentum with consistent earnings beats and bullish technical signals. The stock demonstrates robust fundamentals with 46.34% net margins and 241.49% ROE, supported by growing institutional interest. Recent analyst coverage shows 80% buy ratings with a $666.67 consensus target, indicating significant upside potential from current levels.
Mastercard presents a compelling growth story with expanding global payment volumes and strategic AI investments. Key risks include payment industry disruption from stablecoins and regulatory scrutiny. The company's strong cash flow generation and dividend growth support shareholder returns, though premium valuations require sustained execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
